IPS Extends Global Reach with Local Brazil Office
News Nov 09, 2012
IPS-Integrated Project Services has announced the launch of IPS Integração de Projetos e Serviços.
With a new office in Brazil, IPS enhances its ability to support and accommodate clients growing needs in emerging markets.
IPS-Integração de Projetos e Serviços will operate under the leadership of Francisco Paula Santos, a native of Brazil and an industry executive with extensive experience managing and leading global efforts for major pharmaceutical companies such as Bristol-Myers Squibb (BMS) and Wyeth.
At BMS, he was Vice President of Latin America Technical Operations where he oversaw all operations for Latin Americas.
As General Manger of IPS-Integração de Projetos e Serviços, Mr. Santos will be responsible for the strategic direction and growth of the office in Brazil.
“With a rapidly growing economy, and as the world’s fifth largest country, the Brazil market offers a great deal of opportunity for IPS and our clients,” said Dave Goswami, PE, Chief Executive Officer and Managing Director, IPS.
Goswami continued, “As more and more of our multinational clients are opening facilities in Brazil, as well the local companies intend to construct and/or upgrade its facilities, it is essential for IPS to have a local presence. Our Brazil office will enable us to continue to provide clients with innovative and cost effective business solutions and our superior technical expertise that they have come to expect from our IPS team and brand.”
“Our venture into this region supports our long-term growth strategy and our mission and vision of being the knowledge leaders of choice by helping our clients succeed,” continued Goswami.
“We are excited to have a local presence in Brazil and are confident that Francisco and our local team will deliver the IPS brand in this region and will be able to help our clients maximize their growth potential globally.”
SYGNIS AG Announces Completion of Relocation of its Innova Biosciences UnitNews
Move forms part of integration into SYGNIS Group.READ MORE
Biomarker for Glioblastoma Predicts Clinical Course and Sensitivity to TreatmentNews
Scientists validate a biomarker indicative of patients with Glioblastoma prognosis and likely response to specific therapies.READ MORE
Comments | 0 ADD COMMENT
Annual Conference on Antimicrobials and Drug Resistance
Sep 24 - Sep 25, 2018
1st Alpine Winter Conference on Medicinal and Synthetic Chemistry
Jan 28 - Feb 01, 2018